Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLYCAR T cells in Hepatocellular Carcinoma
NCT02905188Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Mar 2019
- Primary completion
- Nov 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GAP T cells in hepatocellular carcinoma (HCC), sponsored by Baylor College of Medicine. Primary endpoints: Dose Limiting Toxicity at 6 weeks and Recommended Phase 2 Dose at 2 years. Started Mar 2019; status: completed.
02
Drugs
GAP T cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02905188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02905188.